100 Translational Medicine associated with Human fibrinogen/Human antihemophilic factor ⅩⅢ fraction/ Aprotinin solution/Thrombin/Calcium Chloride Hydrate

100 Patents (Medical) associated with Human fibrinogen/Human antihemophilic factor ⅩⅢ fraction/ Aprotinin solution/Thrombin/Calcium Chloride Hydrate

Literatures (Medical) associated with Human fibrinogen/Human antihemophilic factor ⅩⅢ fraction/ Aprotinin solution/Thrombin/Calcium Chloride Hydrate

01 Apr 2022·Journal of Biomedical Materials Research Part AQ3 · ENGINEERING & TECHNOLOGY

Comparative study of hydrophobically modified gelatin‐based sealant with commercially available sealants

Q3 · ENGINEERING & TECHNOLOGY

Article

Author: Sato, Yukio ; Katano, Mayumi ; Yanagihara, Takahiro ; Taguchi, Tetsushi ; Maki, Naoki ; Watanabe, Shiharu ; Mizuno, Yosuke

AbstractAir leakage is one of the major complications related to pulmonary surgeries. To reduce this complication, we developed a decyl group (C10)‐modified Alaska pollock gelatin (ApGltn) (C10‐ApGltn) sealant and evaluated its practical performance against commercially available sealants, Beriplast® and DuraSeal®. C10‐ApGltn was synthesized by reductive amination of the amino groups in ApGltn with decanal. C10‐ApGltn was crosslinked with a poly(ethylene glycol)‐based crosslinker to form a tissue sealant. The crosslinking time of the C10‐ApGltn sealant was fast enough for curing on tissue and application as a spray system. Although the percent swelling of C10‐ApGltn and DuraSeal was significantly greater than Beriplast, C10‐ApGltn and DuraSeal exhibited excellent tissue sealing properties on pleura tissue under a long‐term moist condition. Additionally, C10‐ApGltn and DuraSeal did not cause severe inflammatory responses in a rat subcutaneous example. Therefore, C10‐ApGltn sealant had comparable tissue sealing properties to DuraSeal under a moist condition, indicating the potential of C10‐ApGltn sealant for pulmonary surgeries.

01 Jun 2016·World NeurosurgeryQ4 · MEDICINE

An Experimental Study of Histopathologic Effects of Hemostatic Agents Used in Spinal Surgery

Q4 · MEDICINE

Article

Author: Altun, Idiris

OBJECTIVETo evaluate and compare the histopathologic effects of various hemostatic agents used in spinal surgery on an experimental laminectomy model in rats.METHODSThere were 110 rats randomly allocated into 11 groups, including sham, control, AnkaferdBlood Stopper (herbal hemostatic), SeraSeal (agar and bovine factor proteins), FLOSEAL (gelatin granules and thrombin), SURGIFLO (gelatin paste), HELITENE (absorbable collagen), Beriplast (fibrin sealant containing fibrinogen, factor XIII, and thrombin), TISSEEL (fibrin sealant), BLOODCARE (hemostatic powder), and SURGICEL (oxidized cellulose polymer) groups. Hemostatic agents were applied on the epidural region after laminectomy was performed until the identification of dura mater and nerve root. After a follow-up period of 12 weeks, rats were sacrificed, and histologic sections were performed proximal and distal to laminectomy zone. Groups were histopathologically compared in terms of chronic inflammation, fibrosis, and vascularization.RESULTSThere was no difference between groups in terms of acute inflammation (P = 0.159). Chronic inflammation was more remarkable in the herbal hemostatic group (P = 0.036), and there was severe fibrosis in absorbable collagen hemostatic, fibrin sealant, and powder hemostatic agent groups (P < 0.001). Vascularity was more obvious in herbal hemostatic; fibrin sealant; absorbable collagen; fibrin sealant containing fibrinogen, factor XIII, and thrombin; hemostatic powder; and oxidized cellulose polymer groups (P < 0.001).CONCLUSIONSHemostatic agents can cause notable histopathologic alterations, including inflammation, fibrosis, and vascularity. In this context, flowable hemostats such as gelatin granules and thrombin or gelatin paste seem to provide more promising results in spinal surgery.

01 Jan 2014·Neurologia medico-chirurgicaQ4 · MEDICINE

Experimental Study on the Viscosity and Adhesive Performance of Exogenous Liquid Fibrin Glue

Q4 · MEDICINE

Article

Author: HASEGAWA, Mitsuhiro ; HAYASHI, Takuro ; ADACHI, Kazuhide ; NAGAHISA, Shinya ; INAMASU, Joji ; HIROSE, Yuichi

Exogenous fibrin glue (FG) is highly suitable for neurosurgical procedures, because of its viscosity and adhesive properties. Several FGs are commercially available, but only few reports detail their differences. In the present study, we investigated the viscosity and adhesive performance of two types of FG: one is derived from blood donated in Europe and the United States (CSL Behring's Beriplast(®), BP) and the other is derived from blood donated in Japan (the Chemo-Sero-Therapeutic Research Institute's Bolheal(®), BH). The viscosity test that measured fibrinogen viscosity revealed that BP had significantly higher viscosity than BH. Similarly, the dripping test showed that BP traveled a significantly shorter drip distance in the vertical direction than BH, although the transverse diameter of the coagulated FG did not differ statistically significantly. In the tensile strength test, BP showed superior adhesion performance over BH. The histological study of the hematoxylin-eosin-stained specimens in both groups showed favorable adhesion. Although further studies are required on its manufacturing and usage methods, FG shows differences in viscosity and adhesive performance according to the blood from which it is derived. We conclude that it is desirable to select the type and usage method of FG according to the characteristics of the surgical operation in question. Our findings suggest that FG produced from the blood donated in Europe and the United States might be more suitable for use in surgical procedures that demand an especially high degree of viscosity and rapid adhesive performance.

100 Deals associated with Human fibrinogen/Human antihemophilic factor ⅩⅢ fraction/ Aprotinin solution/Thrombin/Calcium Chloride Hydrate

External Link

KEGG	Wiki	ATC	Drug Bank
-	-	B02BC	-

R&D Status

10 top approved records.

to view more data

Indication	Country/Location	Organization	Date
Wounds and Injuries	France	CSL Behring LLC	01 Apr 2000
Hemorrhage	Germany	CSL Behring GmbH	09 Apr 1998
Tissue Adhesions	Japan	CSL Behring KK	28 Jun 1983

Clinical Result

Indication

Phase

Evaluation

View All Results

Study	Phase	Population	Analyzed Enrollment	Group	Results	Evaluation	Publication Date


ARVO2002	Not Applicable	Pterygium	-	Human Plasma Derived Fibrin Glue (Beriplast P) (Nylon 10-0 sutures)	(bjcdipkovm) = fpuuynfhds mbudogxtxn (iprtcdhzzm ) View more	Positive	01 Dec 2002
				Human derived fibrin glue (Beriplast P)	(bjcdipkovm) = eqpdrzwbhl mbudogxtxn (iprtcdhzzm ) View more

Translational Medicine

Boost your research with our translational medicine data.

view full example data

Deal

Boost your decision using our deal data.

view full example data

Core Patent

Boost your research with our Core Patent data.

view full example data

Clinical Trial

Identify the latest clinical trials across global registries.

view full example data

Approval

Accelerate your research with the latest regulatory approval information.

view full example data

Biosimilar

Competitive landscape of biosimilars in different countries/locations. Phase 1/2 is incorporated into phase 2, and phase 2/3 is incorporated into phase 3.

view full example data

Regulation

Understand key drug designations in just a few clicks with Synapse.

view full example data

Chat with Hiro

Get started for free today!

Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.

Start your data trial now!

Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.

Bio

Bio Sequences Search & Analysis

Chemical

Chemical Structures Search & Analysis

Human fibrinogen/Human antihemophilic factor ⅩⅢ fraction/ Aprotinin solution/Thrombin/Calcium Chloride Hydrate

Overview

Basic Info

Related

External Link

R&D Status

Clinical Result

Translational Medicine

Deal

Core Patent

Clinical Trial

Approval

Biosimilar

Regulation